Gilead, Drug Prices & Medicare Spending

Gilead manufactures 15 drugs tracked by Medicare Part D with total spending of $14.7B.

Drugs Tracked

$14.7B

Medicare Spending

$2,735.34

Avg Cost/Claim

87%

Have Generics

Gilead Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Biktarvy	Bictegravir/Emtricitabine/TAF	$3,746.00	$3.8B	+12.8%	No
2	Genvoya	Elvitegravir/Cobicistat/Emtricitabine/TAF	$3,619.00	$2.3B	-8.4%	Yes
3	Descovy	Emtricitabine/TAF	$2,418.00	$1.6B	+12.4%	Yes
4	Harvoni	Ledipasvir/Sofosbuvir	$24,958.00	$1.2B	-38.2%	No
5	Epclusa	Sofosbuvir/Velpatasvir	$26,143.00	$1.1B	-15.7%	Yes
6	Trodelvy	Sacituzumab Govitecan	$15,643.00	$876.0M	+68.4%	Yes
7	Truvada	Emtricitabine/Tenofovir DF	$2,066.00	$876.0M	-32.4%	Yes
8	Odefsey	Emtricitabine/Rilpivirine/TAF	$3,532.00	$876.0M	-8.4%	Yes
9	Letairis	Ambrisentan	$8,338.00	$567.0M	-4.8%	Yes
10	Complera	Emtricitabine/Rilpivirine/TDF	$4,012.00	$345.0M	-24.6%	Yes
11	Vemlidy	Tenofovir Alafenamide	$1,855.00	$345.0M	+8.4%	Yes
12	Sovaldi	Sofosbuvir	$13,000.00	$234.0M	-42.4%	Yes
13	Sunlenca	Lenacapavir	$9,750.00	$234.0M	0.0%	Yes
14	Vosevi	Sofosbuvir/Velpatasvir/Voxilaprevir	$14,833.00	$178.0M	-28.6%	Yes
15	Ranolazine	Ranolazine	$96.00	$178.0M	-8.6%	Yes

Frequently Asked Questions

Gilead manufactures 15 drugs tracked by Medicare Part D, with total annual spending of $14.7B.

Epclusa (Sofosbuvir/Velpatasvir) is the most expensive at $26,143.00 per claim.

13 of 15 Gilead drugs (87%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.